Chemotherapy used in colorectal cancer treatment can cause several side effects, and careful monitoring is required throughout therapy. Two commonly used treatment regimens are associated with different toxicity profiles. Among these effects, neuropathy and diarrhea are considered the most significant concerns because they can directly affect treatment continuation and patient quality of life.
Neuropathy is one of the most important side effects associated with oxaliplatin-based chemotherapy. This condition may appear in two different forms. The first type is cold-induced neuropathy, which often develops shortly after treatment and may last several days. Patients frequently experience sensitivity to cold temperatures, discomfort, or muscle spasms triggered by exposure to cold air or cold objects. The severity varies from mild discomfort to more pronounced symptoms.
Patient education plays an essential role in preventing cold-triggered events. During warmer months, patients are advised to avoid sudden exposure to strong air conditioning immediately after treatment, as cold air directed toward the face may provoke muscle spasms. In colder seasons, protective measures such as wearing scarves and gloves help maintain warmth in the hands, mouth, and face during the days following chemotherapy. These symptoms may occur even after the first treatment cycle and can become longer-lasting with repeated exposure.
A second form of neuropathy develops gradually and presents as numbness or tingling in the fingers and toes. This peripheral neuropathy is cumulative, meaning symptoms increase as treatment cycles continue. In adjuvant colorectal cancer therapy, patients often aim to complete twelve treatment cycles. However, progressive neuropathy frequently makes completion challenging. Dose reduction, treatment delays, or removal of oxaliplatin from the regimen may become necessary because oxaliplatin is the primary cause of nerve toxicity.
Patients who already have nerve damage before chemotherapy, particularly those with diabetes, require additional monitoring. Coordination with primary care physicians or endocrinologists is important to maintain strict blood glucose control. Proper management of diabetes helps reduce additional nerve injury and limits worsening neuropathy during treatment.
In irinotecan-based chemotherapy regimens, diarrhea represents the most significant treatment-related concern. Diarrhea may occur early, sometimes on the same day as treatment, or several days afterward. Delayed diarrhea can also develop approximately one week following therapy. Since these treatments are typically administered every two weeks, uncontrolled symptoms may interfere with scheduled treatment cycles.
Education regarding diarrhea management is essential from the beginning of therapy. Patients must understand the importance of maintaining adequate hydration and using prescribed anti-diarrheal medications correctly. Early communication with the medical team is critical if symptoms remain uncontrolled despite medication use. Persistent diarrhea can lead to dehydration, hospitalization, and interruption of chemotherapy treatment.
Dietary awareness also supports symptom control. Patients benefit from guidance on suitable foods during treatment, foods that may worsen gastrointestinal irritation, and early warning signs of dehydration such as weakness, dizziness, or reduced urine output. Prompt management helps prevent complications and allows therapy to continue safely.
Overall, neuropathy related to oxaliplatin and diarrhea associated with irinotecan represent the primary challenges during colorectal cancer chemotherapy. Continuous patient education, early symptom reporting, and supportive care strategies are necessary to minimize complications and maintain treatment effectiveness.
